In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Astellas makes $52/share cash offer for OSI Pharmaceuticals

Executive Summary

After over a year of attempting to enter into a friendly arrangement, Astellas Pharma has made a hostile bid to acquire top public biotech firm OSI Pharmaceuticals for $3.03bn in cash, or $52 a share (a 42% premium). In a written response on February 22, 2010, to Astellas' most recent oral proposal, OSI said the offer significantly undervalues the company and it is asking shareholders not to take any action. Astellas has filed a lawsuit to prevent OSI from conducting any activities, such as a "poison pill" plan that would interfere with the tender offer.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash

Related Companies